Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could light therapy help save sight in dry macular degeneration?

NCT ID NCT02725762

Disease control Sponsor: LumiThera, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study investigates whether a non-invasive light treatment called photobiomodulation can improve vision and slow vision loss in people with dry age-related macular degeneration (AMD). Participants receive either active light therapy or a sham (inactive) treatment over 12 months. The goal is to see if this approach can safely help preserve eyesight in those with the condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
light therapy (photobiomodulation) via the LT-300 device
What this could lead to
If effective, this could offer a non-invasive treatment option to help preserve vision in people with dry age-related macular degeneration.
What could go wrong
This is a small, early-stage study with only 30 participants, so results may not apply to everyone. The treatment may not improve vision or could have unknown side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Start date

Mar 2016

Finished

Jul 2018

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients of both gender * Patients must have dry macular degeneration in the study eye * Best corrected visual acuity between 20/40 and 20/200 * Patients must be competent to sign and have signed a consent form before study entry Exclusion Criteria: * Visually significant cataracts. * Presence of a visually significant posterior capsule if prior cataract surgery has been performed. * Any visually significant disease process in any ocular structure that would affect vision unrelated to macular degeneration. * A patient can be enrolled if only one of their eyes meets the criteria. The other eye may be treated but not included in the study; for example advanced geographic atrophy. * Patients with severe clinically significant disease or unstable medical disorders including cardiovascular, hepatic, renal, neurological, endocrine, gastrointestinal, CNS or life threatening disease or current malignancy at the discretion of the investigators * Patients who are non-ambulatory or bed ridden * Female patients who are pregnant or of childbearing potential as effects of PBM on the developing human fetus are unknown. * Patients with a history of Epilepsy * Patients with a history of alcohol, drug or substance abuse in the past 6 months * Patients deemed uncooperative or non compliant with the requirements of the protocol. * Patients who have received any investigational drug or treatment within 30 days prior to study entry. * Patients who are not competent to understand and sign consent form.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age related macular degeneration are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

age-related macular degeneration dry age related macular degeneration macular degeneration vision disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Age related macular degeneration

Contacts and locations

Locations

  • 1929 Bayview Avenue, Unit 117

    Toronto, Ontario, M4G 3E8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.